Open Access
Access granted
Subscription or Fee Access
Vol 23, No 12 (2012)
- Year: 2012
- Articles: 20
- URL: https://journals.eco-vector.com/0236-3054/issue/view/5919
Articles
ALCOHOLIC HEPATITIS: CLINICAL AND MORPHOLOGICAL FEATURES, DIAGNOSIS, TREATMENT
Abstract
The paper provides the clinical and morphological characteristics of acute and chronic alcoholic hepatitis. It analyzes different clinical types of acute alcoholic hepatitis (AAH): icteric (usually a severe type), fulminant, cholestatic, and latent. The possibilities of AAH treatment are considered. Severe AAH serves as an indication for the use of glucocorticosteroids or pentoxifylline; it is sufficient to withdraw from alcohol and to use metabolic agents in moderate alcoholic hepatitis. The paper gives data on the universal action of essentiale on the pathogenetic components of liver damage.
Vrach. 2012;23(12):2-9
2-9
9-14
CURRENT POSSIBILITIES OF PRIMARY AND SECONDARY MEDICAL PREVENTION OF ISCHEMIC STROKE WITH ANTIAGGREGANTS
Abstract
The paper considers the possibilities of using antiaggregant therapy in the primary and secondary medical prevention of ischemic stroke (IS), by taking into account the current European guidelines: the Helsingborg Declaration (2006) and the European Stroke Organization Guidelines of the management of IS and transient ischemic attacks (2008).
Vrach. 2012;23(12):14-17
14-17
THE DIAGNOSIS AND TREATMENT OF VERTIGO IN OUTPATIENT PRACTICE
Abstract
The paper presents an update on the outpatient diagnosis and treatment of the most common causes of vertigo: vestibular migraine, benign paroxysmal positional vertigo, Meniere’s disease, vestibular neuronitis, and psychogenic vertigo. It is pointed out that vertebrobasilar insufficiency and/or cervical osteochondrosis are not a cause of vertigo. Unfortunately, these diagnoses are commonly made as its cause and at the same time fail to define the real causes of vertigo, which can be effectively treated.
Vrach. 2012;23(12):18-21
18-21
RATIONAL PHARMACOTHERAPY IN PSYCHIATRY
Abstract
Techniques for the rational use of psychotropic drugs and pharmacotherapeutic strategies of their utilization are considered from the principles of general and clinical pharmacology. In healthcare practice, difficulties in the rational use of psychotropic agents may be associated with imperfection of their classification, disregard of the dose-effect and time-effect relationships that are well known in pharmacology, and with objective clinical factors. It is emphasized that not only the choice of a drug in accordance with the symptoms of mental disorder, but also making tactic decisions in relation of the phase of treatment for mental disorder are important for the rational use of drugs.
Vrach. 2012;23(12):21-26
21-26
TREATMENT OF DEPRESSION ASSOCIATED WITH CEREBROVASCULAR DISEASE (ACCORDING TO THE DATA OF THE RESONANCE RUSSIAN MULTICENTER NATURALISTIC STUDY)
Abstract
Eighty-eight patients with depression and comorbid cerebrovascular disease were treated with Valdoxan (25-50 mg/day) in the Resonance Russian multicenter naturalistic study. Following 6-week therapy, depressive symptomatology was relieved in the vast majority (82.35%) of patients. 17-item Hamilton Depression Rating Scale (HAMD-17) scores decreased from 15.8±3.6 to 5.0±2.7 (p<0.00001). There was also a reduction in the intractable symptoms of depression (fatigability, low work efficiency, dyssomnia) and their negative impact on patient functioning.
Vrach. 2012;23(12):26-29
26-29
PROSPECTS FOR THE USE OF MODERN FLUOROQUINOLONES IN SURGICAL SKIN AND SOFT TISSUE INFECTIONS, AND BONE AND JOINT INFECTIONS
Abstract
A broad antimicrobial spectrum of modern fluoroquinolones as well as favorable pharmacokinetic profile and potential for overwhelming several bacterial resistance mechanisms make this drug class essential in the treatment of polymicrobial infections at different body sites. This paper presents data on a high efficacy of moxifloxacin in surgical skin and soft tissue infections, and data supporting its use in the treatment of bone and joint infections.
Vrach. 2012;23(12):30-33
30-33
34-38
ANTIHYPERTENSIVE EFICACY OF NOLIPREL A BI-FORTE IN RELATION TO THE PRESENCE OF LEFT VENTRICULAR HYPERTROPHY
Abstract
The treatment of arterial hypertension (AH), in patients with target organ lesion in particular, presents considerable difficulties. The full-dose combination of perindopril A (10 mg) indapamide (2,5 mg) (Noliprel A Bi-Forte) is shown to lower blood pressure (BP) in patients with left ventricular hypertrophy to the same degree as in those without target organ lesions and may be effectively used as starting therapy. It is expedient to use 24-hour BP monitoring to control the efficiency of therapy and to decide whether it should be corrected.
Vrach. 2012;23(12):38-41
38-41
A FIXED-DOSE COMBINATION OF AMLODIPINE AND LISINOPRIL: THE ADVANTAGES OF ITS USE IN METABOLIC SYNDROME
Abstract
The authors consider the benefits of a fixed-dose combination of amlodipine and lisinopril (Ekvator, Gedeon Richter) and the advantages of its use in the treatment of obese patients with arterial hypertension. The drug provides effective blood pressure control and secondary prevention of cardiovascular events in patients with metabolic syndrome and slows the progression of atherosclerosis.
Vrach. 2012;23(12):42-45
42-45
SECONDARY PREVENTION OF ISCHEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES MELITUS
Abstract
Inadequate glycemic control and a higher risk for hypoglycemic states during therapy are among the reasons for a 6-fold increase in the incidence rate of stroke in patients with type 2 diabetes mellitus (DM2). Sitagliptin is a current dipeptidyl peptidase-4 inhibitor, a glucose-lowering agent that promotes the prevention of macro- and microvascular complications in patients with DM2.
Vrach. 2012;23(12):45-50
45-50
EFFICACY OF TANAKAN IN THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PATIENTS WITH CHRONIC BRAIN ISCHEMIA
Abstract
The paper discusses the clinical aspects of the impact of chronic brain ischemia on cerebral cortical structures to develop impairments in higher nervous activity and cognitive (gnostic) functions. It gives the results of using Tanakan® to treat cognitive impairments in patients with chronic brain ischemia.
Vrach. 2012;23(12):50-57
50-57
57-60
THE EFFICIENCY, SAFETY, AND TOLERANCE OF ROSUVASTATIN THERAPY IN VERY HIGH CARDIOVASCULAR RISK PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: PRELIMINARY RESULTS OF THE 40x40 STUDY
Abstract
The main objective of the pilot 40 x 40 study was to evaluate the hypolipidemic efficacy, safety, and tolerance of the generic rosuvastatin Mertenil in a high daily dose of 40 mg/day in very high cardiovascular risk patients who failed to achieve low-density lipoprotein cholesterol goals during current statin therapy in daily clinical practice. The data of a follow-up during the first 12-week therapy are given.
Vrach. 2012;23(12):61-65
61-65
MAGNESIUM PREPARATIONS FOR PAIN SYNDROMES IN PATIENTS WITH PERIPHERAL NERVOUS SYSTEM DISEASES
Abstract
Prospects for using magnesium preparations in chronic pain syndromes caused by peripheral nervous system lesion are discussed. Magnerot® (magnesium orotate) is shown to be effective in the treatment of chronic pain in patients with diabetic polyneuropathy and radiculopathy.
Vrach. 2012;23(12):65-68
65-68
EVALUATION OF CEREBRAL METABOLISM IN DYSCIRCULATORY ENCEPHALOPATHY
Abstract
Progressive dyscirculatory encephalopathy may give rise to permanent neurological defect and reduced quality of life. In chronic cerebrovascular diseases, positron emission tomography can reveal cerebral metabolic disturbances unaccompanied by respective focal structural changes on computed tomography and magnetic resonance scans.
Vrach. 2012;23(12):69-72
69-72
PREDUCTAL MV: EFFECT ON EFFICIENCY OF THERAPY AND QUALITY OF LIFE IN PATIENTS WITH VENTRICULAR ARRHYTHMIAS AND METABOLIC SYMDROME
Abstract
The impact of intake of the myocardial metabolic cytoprotector trimetazidine (Preductal MB) on the efficiency of antiarrhythmic, antianginal therapy and quality of life was evaluated in patients with ventricular arrhythmias (VA), coronary heart disease (CHD), and metabolic syndrome (MS). The investigation enrolled 36 patients with VA and MS who received antiarrhythmic and MS therapies; half of the randomized was additionally given trimetazidine (Preductal MB). According to the data of the investigation, MS therapy using trimetazidine (Preductal MB) in patients with VA and CHD results in a significant improvement in quality of life and exercise tolerance and in higher efficiency of antiarrhythmic and antianginal therapy.
Vrach. 2012;23(12):72-76
72-76
CHRONIC CONSTIPATION: VIEWS, PATHOGENESIS, DIAGNOSIS, NEW POSSIBILITIES OF TREATMENT
Abstract
The paper considers the problem of chronic constipation, the etiopathogenetic aspects of development of this abnormality, its current classification and new treatments. It gives the basic groups of laxatives with estimation of their therapeutic capacities. The efficacy and tolerance of the new laxative containing micronized lactulose coated with condensed liquid paraffin, which has an original mechanism of action, are evaluated.
Vrach. 2012;23(12):77-82
77-82
82-84
MAJOR DETERMINANTS OF THE HEALTH STATUS IN THE ADULT POPULATION OF AN INDUSTRIAL TOWN
Abstract
The major determinants of the health status was estimated in the adult population of an industrial town, such as socioeconomic, behavioral, medico-organizational, and technogenic (long-term low-dose ionizing radiation) risk factors. The key risk factors influencing the health status of the adult population of an industrial town were shown to be socioeconomic, behavioral, and medico-organizational; there is no strong evidence suggesting that there is a threat to life when living in the exposure area of an atomic industry enterprise.
Vrach. 2012;23(12):86-88
86-88